Cita APA (7a ed.)
Del Prete, M., Buteau, F., Arsenault, F., Saighi, N., Bouchard, L., Beaulieu, A., & Beauregard, J. (2019). Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: Initial results from the P-PRRT trial. European Journal of Nuclear Medicine & Molecular Imaging, 46(3), 728-743.
Cita Chicago Style (17a ed.)
Del Prete, Michela, François-Alexandre Buteau, Frédéric Arsenault, Nassim Saighi, Louis-Olivier Bouchard, Alexis Beaulieu, y Jean-Mathieu Beauregard. "Personalized 177Lu-octreotate Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumours: Initial Results from the P-PRRT Trial." European Journal of Nuclear Medicine & Molecular Imaging 46, no. 3 (2019): 728-743.
Cita MLA (9a ed.)
Del Prete, Michela, et al. "Personalized 177Lu-octreotate Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumours: Initial Results from the P-PRRT Trial." European Journal of Nuclear Medicine & Molecular Imaging, vol. 46, no. 3, 2019, pp. 728-743.
Precaución: Estas citas no son 100% exactas.